Child DevelopmentNCT04508257
The Effect of a New Infant Formula on Growth and Cognition in Healthy Term Infants
A study testing Oral feeding of Investigational Formula (Stage 1&2) and Breast feeding in people with Child Development, run by Heilongjiang Feihe Dairy Co. Ltd. at 3 sites in China.
Trial summary
This study is a multicenter, double-blind, randomized, controlled, parallel-designed, prospective trial and is intended to evaluate the nutritive effects of two staged study formulas on growth and cognitive outcomes. Read more about this study
- Who is it for?
- Ages 30 to 30 daysHealthy volunteers can take part
- Conditions the study is for
- Child Development
- What is being tested?
- Oral feeding of Investigational Formula (Stage 1&2) and Breast feeding
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 450 participants
- Where
- 3 sitesChina
- Study dates
- 1 Aug 2020to 28 Feb 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 30 days
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- 30 days of age at randomization, inclusive (day of birth is considered day 0)
- Exclusively formula-fed for at least 3 days prior to randomization
- Singleton birth
- Gestational age of 37-42 weeks (36 weeks and six days is considered 36 weeks gestational age)
- Birth weight of 2500g to 4000g
- Signed informed consent obtained for infant's participation in the study
- Parent or guardian of infant agrees not to enroll infant in another interventional clinical research study while participating in this study
Who cannot join
- History of underlying metabolic or chronic disease; congenital malformation; or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the infant to ingest food, the normal growth and development of the infant, or the evaluation of the infant
- Evidence of feeding difficulties or formula intolerance, such as vomiting or poor intake, at time of randomization (at investigator discretion)
- Weight at Visit 1 is <95% of birth weight [(weight at Visit 1÷birth weight) x 100 <95%]
- Infant is immunocompromised (according to a doctor's diagnosis of immunodeficiency such as Combined Immunodeficiencies, DiGeorge Syndrome, Wiskott-Aldrich Syndrome, Severe Congenital Neutropenia and Secondary Immunodeficiencies linked to HIV infection, Down Syndrome or others) and children with known head/brain disease/injury such as Microcephaly, Macrocephaly or others.
- History of underlying metabolic or chronic disease; congenital malformation; or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the infant to ingest food, the normal growth and development of the infant, or the evaluation of the infant
- Evidence of feeding difficulties or formula intolerance, such as vomiting or poor intake, at time of randomization (at investigator discretion)
Show all 13Show fewer
- Weight at Visit 1 is <95% of birth weight [(weight at Visit 1÷birth weight) x 100 <95%]
- Infant is immunocompromised (according to a doctor's diagnosis of immunodeficiency such as Combined Immunodeficiencies, DiGeorge Syndrome, Wiskott-Aldrich Syndrome, Severe Congenital Neutropenia and Secondary Immunodeficiencies linked to HIV infection, Down Syndrome or others) and children with known head/brain disease/injury such as Microcephaly, Macrocephaly or others.
- Additional Criteria for Inclusion in the Stool Collection Subset
- Vaginal birth
- Participant has not received antibiotic treatment antibiotic and/or corticosteroid treatment for at least 30 days prior to the collection.
- Participant has not consumed prebiotics/probiotics supplements
- Parent/caregiver has access to a home freezer for sample storage
Trial locations and contacts
3 sites in 1 country.
China3 sites, 3 recruiting
- Recruiting
Jinhua Nanyuan Community Health Center (site 1919)
Jinhua, Zhejiang
Melody Hou, +86 133 2198 2383, 13321982383@163.com
- Recruiting
Jinhua Qiubin Community Health Center (site 1969)
Jinhua, Zhejiang
Melody Hou, +86 133 2198 2383, 13321982383@163.com
- Recruiting
Jinhua Xiguan Community Health Center (site 1966)
Jinhua, Zhejiang
Melody Hou, +86 133 2198 2383, 13321982383@163.com
About this study
Official title: Randomized, Double-blind, Parallel, Controlled Study to Evaluate the Nutritive Effects of Two Staged Infant Formulas on Growth and Cognitive Outcomes in Healthy Term Infants
This study is a multicenter, double-blind, randomized, controlled, parallel-designed, prospective trial and is intended to evaluate the nutritive effects of two staged study formulas on growth and cognitive outcomes. Approximately 450 participants will be enrolled with the expectation of having 105 participants per group (315 for three groups: control group, investigational group, and breastfeeding reference group ) complete Study Visit 6 at 365 days of age ± 7 days (allowing for a 30% drop-out rate). Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age. The study period will include feeding up to 365 days of age and cognitive testing up to 365 days of age. Stool samples will be collected from a subset of participants at enrollment and at 120 days of age for fecal microbiome analysis.
Read the detailed description
Primary Objective
- Compare measures of normal, healthy mental development at 365 days of age among infants receiving an investigational formula, infants receiving the control and breastfed group.
Secondary Objectives
To compare between the two study groups:
- Measures of mental development up to 365 days of age
- Rate of body weight, length and head circumference gain
- Achieved weight, length and head circumference
- Stool characteristics, tolerance and formula acceptance
- Fecal microbiome analysis
- Antibiotic treatment
- Medically-confirmed adverse
- Conditions
- Child Development
- Being tested
- Oral feeding of Investigational Formula (Stage 1&2), Oral feeding of Control formula (Stage 1&2), Breast feeding
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oral feeding of Investigational Formula (Stage 1&2)Dietary supplement
Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age.
Oral feeding of Control formula (Stage 1&2)Dietary supplement
Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age.
Breast feedingDietary supplement
Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
| Study group | Role | What they receive |
|---|---|---|
| Investigational Formula (Stage 1&2) | Experimental | Investigational formula contains DHA,ARA and enriched whey protein (source of milk fat globule membrane) to support the healthy growth and Cognitive development of infants. Receives: Dietary Supplement: Oral feeding of Investigational Formula (Stage 1&2) |
| Control formula (Stage 1&2) | Active comparator | Control formula have comparable macronutrients and micronutrients, but does not contain DHA,ARA and MFGM. Receives: Dietary Supplement: Oral feeding of Control formula (Stage 1&2) |
| Breast feeding | Other | Breast fed of human milk Receives: Dietary Supplement: Breast feeding |
What is being measured
The primary outcome is the main question the study is designed to answer.
Infant cognitive development
Cognitive Scale of the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) is used to evaluate infant cognitive development at 365 days of age.
- Unabbreviated scale title: Bayley-III Scales of Infant Development Tables and Graphs Report-- Cognitive Scale ;
- Bayley-III contains two scoring systems of composite scores and percentile ranks. The normal range for composite scores is between 40-160 with mean at 100 and 0-99 for the percentile ranks.
- Higher scores mean a better outcome.
Measured: at 365 days of age
Secondary outcomes (19)
Infant Language capabilities
Language Scale of Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) is used to evaluate the infant Language capabilities at 365 days of age.
- Unabbreviated scale title:Bayley-III Scales of Infant Development Tables and Graphs Report-- Language Scale ;
- Bayley-III contains two scoring systems of composite scores and percentile ranks. The normal range for composite scores is between 40-160 with mean at 100 and 0-99 for the percentile ranks.
- Higher scores mean a better outcome.
Measured: at 365 days of age
Infant motor skills
Motor Scale of Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) is used to evaluate the infant motor skills at 365 days of age.
- Unabbreviated scale title:Bayley-III Scales of Infant Development Tables and Graphs Report-- Motor Scale
- Bayley-III contains two scoring systems of composite scores and percentile ranks. The normal range for composite scores is between 40-160 with mean at 100 and 0-99 for the percentile ranks.
- Higher scores mean a better outcome.
Measured: at 365 days of age
Infant social-emotional capabilities
Social-emotional Scale of Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) is used to evaluate the infant social-emotional capabilities at 365 days of age.
- Unabbreviated scale title:Bayley-III Scales of Infant Development Tables and Graphs Report-- Social-emotional Scale.
- Bayley-III contains two scoring systems of composite scores and percentile ranks. The normal range for composite scores is between 40-160 with mean at 100 and 0-99 for the percentile ranks.
- Higher scores mean a better outcome.
Measured: at 365 days of age
Infant adaptive behavior tests
Adaptive behavior Scale of Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) is used as the infant adaptive behavior assessment tool at 365 days of age.
- Unabbreviated scale title:Bayley-III Scales of Infant Development Tables and Graphs Report-- Adaptive behavior scale
- Bayley-III contains two scoring systems of composite scores and percentile ranks. The normal range for composite scores is between 40-160 with mean at 100 and 0-99 for the percentile ranks.
- Higher scores mean a better outcome.
Measured: at 365 days of age
Ages and Stages Questionnaires (ASQ)
Ages and Stages Questionnaires (ASQ) is administered at 120, 180, and 275 days of age.
ASQ is a developmental screening system comprised of age-specific questionnaires which measure 5 domains of infant development.
- Unabbreviated scale title: Ages and Stages Questionnaires;
- the minimum~maximum value:0~60 points;
- Higher scores mean a better outcome.
Measured: at 120, 180, and 275 days of age
MacArthur-Bates Communicative Development Inventory(CDI) tests
MacArthur-Bates Communicative Development Inventory (CDI) tests is administered at 365 days of age.
It is a parent-report measure that has been validated against actual child language diaries.
- Unabbreviated scale title:MacArthur-Bates Communicative Development Inventory evaluation form
- the minimum~maximum percentile:5%-99%;
- The higher the percentile, the better;
Measured: at 365 days of age
Carey Toddler Temperament Scale( TTS )tests
Carey Toddler Temperament Scale (TTS) tests is administered at 365 days of age. TTS is a 97-item questionnaire which measures the nine categories of temperament: activity level, regularity, adaptability, approach-withdrawal, intensity, mood, persistence, sensory threshold and distractibility.
- Unabbreviated scale title:Carey Toddler Temperament Scale
- Normal score range of TTS for 1 to 3 year old infants: Activity: 12.4 ~ 19.6 Fitness: 6.5 ~ 11.9 Emotional nature: 8.9 ~ 14.1 Regularity: 8 ~ 13 intensity: 11.5 ~ 18.1 Degree of distraction: 8 ~ 12.4 Below or above the normal range are temperament bias.
- Temperament is innate and there is no difference between good and bad. infants with different temperament need different care.
Measured: at 365 days of age
Infant attention
Single object attention and free play tasks is used to measure the infant's attention capabilities. The tasks assess overall fixation (attention) and looking away (inattention) in regards to novel and familiar objects.
Measured: at 365 days of age
Achieve body weight
Achieve body weight (grams) of infants and toddlers at each study visit
Measured: at 30, 90, 120, 180, 275, and 365 days of age
Achieve body length
Achieve body length (cm) of infants and toddlers at each study visit
Measured: at 30, 90, 120, 180, 275, and 365 days of age
Achieve head circumference
Achieve head circumference (cm) of infants and toddlers at each study visit
Measured: at 30, 90, 120, 180, 275, and 365 days of age
24-Hour dietary recall of Formula intake
The parent/caregiver need to record the amount of study formula consumed as well as any other infant formula or milk consumed since the last study visit
Measured: at 30, 90, 120, 180, 275, and 365 days of age
24-Hour Recall of Stool Characteristics Questionnaire
The parent/caregiver will also be asked to recall the number of bowel movements and the stool consistency seen most often over the 24-hour period. Pictures will be provided to the participant's parent or caregiver for use as a guide in rating the stool consistency.
Questionnaire: What stool consistency was seen most often in your baby's bowel movements over the past 24 hours?(Use pictures provided for reference) (0) No bowel movement;
- Hard- dry, hard pellets;
- Formed- definite shape, not dry;
- Soft-no definite shape, pasty;
- Unformed or seedy- no shape, some water or small lumps ;
- Waterly- no shape, mainly water
For option 0~5, 0 and 1 represent poor stool Characteristics , 2-5 represent fine stool Characteristics.
Measured: at 30, 90, 120, 180, 275, and 365 days of age
24-Hour Recall of Tolerance Questionnaire
Tolerance information concerning how fussy and gassy the infant has been and if the infant has been more fussy and/or gassy than normal need to be recalled and recorded by parent/caregiver for the 24-hour period prior to the study visit.
Questionnaire:
- Over the past 24 hours, how fussy has your baby been? (0) Not at all fussy; (1)Slightly fussy; (2) Moderately fussy; (3) Very fussy; (4) Extremely fussy;
- Over the past 24 hours, ____ was your baby? (0) Less fussy than normal ; (1) About the same level of fussiness as always; (2) More fussy than normal
- Over the past 24 hours, how much gas has your baby had? (0) Not at all ; (1) Slightly amount of gas; (2) Moderate amount of gas; (3) Excessive amount of gas
- Over the past 24 hours, did your baby have : (0) Less gas than normal; (1) About the same amount of gas as normal ; (2) More gas than normal
For Question 1 ~ 4, the lower the score, the better.
Measured: at 30, 90, 120, 180, 275, and 365 days of age
Percentages of adverse events
Number and percentages of infants in each group experiencing any medically-confirmed adverse events and any serious adverse events.
- A medically-confirmed adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding that is considered clinically relevant by the Health Care Provider), including eyes, ear, nose and throat and the whole body manifestations, respiratory manifestations, dermatologic manifestations, Musculoskeletal manifestations, Metabolism and nutrition manifestations,etc.
- An adverse event is considered serious if it meets one or more of the following criteria:
- results in death
- is life-threatening
- requires inpatient hospitalization or prolongation of existing hospitalization
- results in persistent or significant disability/incapacity, or
- is a congenital anomaly/birth defect
Measured: from 30 days of age to 365 days of age
Stool collection
Fecal microbiome analysis of samples collected at enrollment and at 120 days of age
Measured: at enrollment and 120 days of age
Percentage of infants with oral antibiotic treatments
Percentage(%) of infants in each group using any oral antibiotic treatments.
Measured: at 365 days of age
Percentage of infants with intramuscular antibiotic treatments
Percentage(%) of infants in each group using intramuscular antibiotic treatments.
Measured: at 365 days of age
Percentage of infants with intravenous (IV) antibiotic treatments
Percentage(%) of infants in each group using intravenous (IV) antibiotic treatments.
Measured: at 365 days of age
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2020
- Study start1 Aug 2020
- Primary completion28 Feb 2023 (estimated)
- Study completion28 Feb 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Child DevelopmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 450 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Heilongjiang Feihe Dairy Co. Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Gong Zhang, M.D., Ph.D., Principal investigator, Anhui Medical University Affiliated Children's Hospital, China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04508257
- Sponsor's protocol ID
- 19-SM-09-FEIHE-001
- Status last verified
- Aug 2020
- First submitted
- 2 Aug 2020
- Last updated
- 18 Aug 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized, Double-blind, Parallel, Controlled Study to Evaluate the Nutritive Effects of Two Staged Infant Formulas on Growth and Cognitive Outcomes in Healthy Term Infants
- ClinicalTrials.gov ID
- NCT04508257
- Acronym / sponsor ID
- 19-SM-09-FEIHE-001
- Conditions
- Child Development
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 450 participants (estimated)
- Lead sponsor
- Heilongjiang Feihe Dairy Co. Ltd.Industry (pharma, biotech, devices)
- Study start
- 1 Aug 2020 (actual)
- Primary completion
- 28 Feb 2023 (estimated)
- Study completion
- 28 Feb 2023 (estimated)
- First posted
- 11 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a multicenter, double-blind, randomized, controlled, parallel-designed, prospective trial and is intended to evaluate the nutritive effects of two staged study formulas on growth and cognitive outcomes. Approximately 450 participants will be enrolled with the expectation of having 105 participants per group (315 for three groups: control group, investigational group, and breastfeeding reference group ) complete Study Visit 6 at 365 days of age ± 7 days (allowing for a 30% drop-out rate). Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age. The study period will include feeding up to 365 days of age and cognitive testing up to 365 days of age. Stool samples will be collected from a subset of participants at enrollment and at 120 days of age for fecal microbiome analysis.
Detailed description
Primary Objective
- Compare measures of normal, healthy mental development at 365 days of age among infants receiving an investigational formula, infants receiving the control and breastfed group.
Secondary Objectives
To compare between the two study groups:
- Measures of mental development up to 365 days of age
- Rate of body weight, length and head circumference gain
- Achieved weight, length and head circumference
- Stool characteristics, tolerance and formula acceptance
- Fecal microbiome analysis
- Antibiotic treatment
- Medically-confirmed adverse
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Investigational Formula (Stage 1&2) | Experimental | Dietary Supplement: Oral feeding of Investigational Formula (Stage 1&2)Investigational formula contains DHA,ARA and enriched whey protein (source of milk fat globule membrane) to support the healthy growth and Cognitive development of infants. |
| Control formula (Stage 1&2) | Active comparator | Dietary Supplement: Oral feeding of Control formula (Stage 1&2)Control formula have comparable macronutrients and micronutrients, but does not contain DHA,ARA and MFGM. |
| Breast feeding | Other | Dietary Supplement: Breast feedingBreast fed of human milk |
Who may qualify
- Ages
- 30 to 30 days
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (7 listed)
- 30 days of age at randomization, inclusive (day of birth is considered day 0)
- Exclusively formula-fed for at least 3 days prior to randomization
- Singleton birth
- Gestational age of 37-42 weeks (36 weeks and six days is considered 36 weeks gestational age)
- Birth weight of 2500g to 4000g
Key exclusion criteria (13 listed)
- History of underlying metabolic or chronic disease; congenital malformation; or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the infant to ingest food, the normal growth and development of the infant, or the evaluation of the infant
- Evidence of feeding difficulties or formula intolerance, such as vomiting or poor intake, at time of randomization (at investigator discretion)
- Weight at Visit 1 is <95% of birth weight [(weight at Visit 1÷birth weight) x 100 <95%]
- Infant is immunocompromised (according to a doctor's diagnosis of immunodeficiency such as Combined Immunodeficiencies, DiGeorge Syndrome, Wiskott-Aldrich Syndrome, Severe Congenital Neutropenia and Secondary Immunodeficiencies linked to HIV infection, Down Syndrome or others) and children with known head/brain disease/injury such as Microcephaly, Macrocephaly or others.
- History of underlying metabolic or chronic disease; congenital malformation; or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the infant to ingest food, the normal growth and development of the infant, or the evaluation of the infant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oral feeding of Investigational Formula (Stage 1&2)Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age. | Dietary supplement | Investigational Formula (Stage 1&2) |
| Oral feeding of Control formula (Stage 1&2)Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age. | Dietary supplement | Control formula (Stage 1&2) |
| Breast feedingExclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula. | Dietary supplement | Breast feeding |
Primary outcome
Infant cognitive development
Time frame: at 365 days of age
Cognitive Scale of the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) is used to evaluate infant cognitive development at 365 days of age. 1. Unabbreviated scale title: Bayley-III Scales of Infant Development Tables and Graphs Report-- Cognitive Scale ; 2. Bayley-III contains two scoring systems of composite scores and percentile ranks. The normal range for composite scores is between 40-160 with mean at 100 and 0-99 for the percentile ranks. 3. Higher scores mean a better outcome.
19 secondary outcomes
Infant Language capabilities
Time frame: at 365 days of age
Infant motor skills
Time frame: at 365 days of age
Infant social-emotional capabilities
Time frame: at 365 days of age
Infant adaptive behavior tests
Time frame: at 365 days of age
Ages and Stages Questionnaires (ASQ)
Time frame: at 120, 180, and 275 days of age
MacArthur-Bates Communicative Development Inventory(CDI) tests
Time frame: at 365 days of age
Carey Toddler Temperament Scale( TTS )tests
Time frame: at 365 days of age
Infant attention
Time frame: at 365 days of age
Achieve body weight
Time frame: at 30, 90, 120, 180, 275, and 365 days of age
Achieve body length
Time frame: at 30, 90, 120, 180, 275, and 365 days of age
Achieve head circumference
Time frame: at 30, 90, 120, 180, 275, and 365 days of age
24-Hour dietary recall of Formula intake
Time frame: at 30, 90, 120, 180, 275, and 365 days of age
24-Hour Recall of Stool Characteristics Questionnaire
Time frame: at 30, 90, 120, 180, 275, and 365 days of age
24-Hour Recall of Tolerance Questionnaire
Time frame: at 30, 90, 120, 180, 275, and 365 days of age
Percentages of adverse events
Time frame: from 30 days of age to 365 days of age
Stool collection
Time frame: at enrollment and 120 days of age
Percentage of infants with oral antibiotic treatments
Time frame: at 365 days of age
Percentage of infants with intramuscular antibiotic treatments
Time frame: at 365 days of age
Percentage of infants with intravenous (IV) antibiotic treatments
Time frame: at 365 days of age
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2020.
Related trials for Child Development
RecruitingPhase 1
Cannabidiol (CBD) in Adults With ASD
Autism Spectrum Disorder
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Sensory-integration Therapy Verses Augumented Reality-based Training in ASD
Autism Spectrum Disorder
Not yet recruiting
Hearing Intervention Effects on Brain and Language Development in Children With Bilateral Mild Hearing Loss
Hearing Loss, Bilateral
Recruiting
Cumulative and Booster Effects of Multisession Prefrontal tDCS in ASD Adolescents
Transcranial Direct Current Stimulation, Autistic Spectrum Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gong Zhang, M.D., Ph.D. principal investigator
Anhui Medical University Affiliated Children's Hospital, China
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Oral feeding of Investigational Formula (Stage 1&2) and Breast feeding in people with Child Development, run by Heilongjiang Feihe Dairy Co. Ltd. at 3 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Li Zhang, MD (+86 21 51097272, charlie.zhang@sprim.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Infant cognitive development (time frame: at 365 days of age). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2020.